熱門資訊> 正文
Aurinia Pharma超出第二季度预期,缩小财年收入指引
2024-08-01 18:05
- Aurinia Pharma press release (NASDAQ:AUPH): Q2 GAAP EPS of $0.01 in-line.
- Revenue of $57.2M (+37.9% Y/Y) beats by $2.51M.
- Shares +2.72% PM.
- Company narrows 2024 net product revenue guidance range to $210 to $220 million
More on Aurinia Pharma
- Aurinia Pharmaceuticals Appears Undervalued
- Aurinia Pharma Q2 2024 Earnings Preview
- Seeking Alpha’s Quant Rating on Aurinia Pharma
- Historical earnings data for Aurinia Pharma
- Financial information for Aurinia Pharma
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。